Amneal Pharmaceuticals, Inc. (AMRX)

Name: Amneal Pharmaceuticals, Inc. (AMRX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001723128 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, Amneal Pharmaceuticals, Inc. reported revenue of $3.02B. Revenue grew 8.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $3.12B.

Key ratios (year ended 2025-12-31)

36.9%

Gross margin

13.1%

Operating margin

2.4%

Net margin

8.0%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-21

Headquarters locality: Hayward / Bridgewater Township · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$3.12B	$3.02B	$2.79B	$2.39B	$2.21B	$2.09B	$1.99B	$1.63B	$1.66B	$1.03B	$1.02B
Cost of Revenue	$1.89B	$1.91B	$1.77B	$1.57B	$1.43B	$1.32B	$1.33B	$1.15B	$938.77M	$507.48M	$420.77M
Gross Profit	$1.23B	$1.11B	$1.02B	$820.57M	$784.71M	$768.97M	$628.39M	$353.00M	$716.40M	$526.18M	$597.46M
R&D Expense	$175.57M	$186.18M	$190.71M	$163.95M	$195.69M	$201.85M	$179.93M	$188.05M	$194.19M	$171.42M	$179.02M
Operating Income	$453.92M	$394.10M	$249.33M	$204.37M	-$94.93M	$152.72M	$91.16M	-$248.68M	-$19.67M	$245.10M	$284.88M
Net Income	$157.36M	$72.06M	-$116.89M	-$83.99M	-$270.58M	$13.16M	$67.79M	-$603.57M	-$19.74M	$0	$0
EPS (Diluted)	n/a	$0.22	-$0.38	-$0.48	-$0.86	$0.07	$0.61	-$2.74	-$0.16	n/a	n/a
Total Assets	$3.78B	$3.68B	$3.50B	$3.47B	$3.80B	$3.94B	$4.01B	$3.67B	$4.35B	$1.34B	n/a
Total Liabilities	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$0	n/a
Long-Term Debt	$2.57B	$2.57B	$2.39B	$2.42B	$2.62B	$2.71B	$2.78B	$2.63B	$2.65B	$1.44B	n/a
Shareholders' Equity	$33.02M	-$70.79M	-$109.27M	$19.78M	$298.42M	$360.34M	$303.27M	$232.01M	$504.75M	$0	n/a
Cash & Equivalents	$127.64M	$282.03M	$110.55M	$91.54M	$25.98M	$247.79M	$341.38M	$151.20M	$213.39M	$74.17M	$27.37M
Operating Cash Flow	$200.78M	$339.99M	$295.10M	$345.58M	$65.10M	$241.82M	$379.00M	$1.71M	$250.23M	$234.19M	$115.06M
Capital Expenditures	$72.94M	$70.06M	$51.92M	$43.22M	$46.41M	$47.73M	$56.45M	$47.18M	$83.09M	$94.77M	$122.76M
Free Cash Flow	$127.83M	$269.93M	$243.18M	$302.36M	$18.69M	$194.09M	$322.56M	-$45.48M	$167.14M	$139.42M	-$7.70M
Dividends Paid	n/a	n/a	n/a	n/a	n/a	n/a	$0	$0	$183.00M	$375.26M	$200.62M
Shares Outstanding	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1.0K	n/a
Weighted Average Diluted Shares	n/a	324.81M	308.98M	176.14M	150.94M	151.82M	148.91M	132.11M	127.25M	n/a	n/a
EPS (Basic)	n/a	$0.23	-$0.38	-$0.48	-$0.86	$0.07	$0.62	-$2.74	-$0.16	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView